Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Pembrolizumab, Olaparib and Temozolomide for the Treatment of Recurrent Glioblastoma

Trial Status: temporarily closed to accrual

This phase II trial tests how well the combination of pembrolizumab, olaparib and temozolomide works in treating patients with glioblastoma that that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged DNA. Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is a chemotherapy drug that can enter the brain and prevent tumor cells from growing by causing DNA damage. The combination of pembrolizumab, olaparib and temozolomide may be an effective treatment for patients with recurrent glioblastoma.